ATNM Stock Forecast: Actinium Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.05
−1.87% on the day

The median 12-month analyst price target for Actinium Pharmaceuticals, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 87 of 100 as at 21 Nov 2026 — inside the top quartile.

Market cap
$42.4M
Ticker Nerd rank
87/ 100
Median analyst target
$4.00
Analysts covering
3
Revenue$35.0M
Operating income$27.6M
Net income$27.9M
Free cash flow−$5.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−36.0%
1M
−25.0%
YTD
−22.8%
1Y
−18.6%
From 52W high
−37.9%
From 52W low
+40.2%
$0.75
$1.69
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Actinium Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
87/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
100
Value
94
Quality
83
Revisions
61
Momentum
52
Issuance
46
Volatility
43
Accruals
27

Growth (100): Sales and profits are climbing, and climbing faster than before.

Accruals (27): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ATNM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATNM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26ATNMHigh $7.00Median $4.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3
Buy
0
Hold
0
Sell
$3.00
Low
$4.00
Median
$7.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Mar 2026Stephens & Co.ReiteratesOverweight—
24 June 2025HC Wainwright & Co.ReiteratesBuy—
12 May 2025HC Wainwright & Co.ReiteratesBuy—
28 Apr 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
27 Mar 2025HC Wainwright & Co.ReiteratesBuy—
25 Mar 2025HC Wainwright & Co.ReiteratesBuy—
20 Mar 2025HC Wainwright & Co.ReiteratesBuy—
18 Mar 2025HC Wainwright & Co.ReiteratesBuy—
11 Mar 2025HC Wainwright & Co.ReiteratesBuy—
19 Nov 2024Stephens & Co.ReiteratesOverweight—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
6 Aug 2024HC Wainwright & Co.MaintainsBuy—
6 Aug 2024Maxim GroupMaintainsBuy—
26 July 2024HC Wainwright & Co.ReiteratesBuy—
17 June 2024HC Wainwright & Co.ReiteratesBuy—
21 May 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024Stephens & Co.InitiatesOverweight—
2 May 2024HC Wainwright & Co.ReiteratesBuy—
30 Apr 2024Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ATNM.

Market Radar

This page is one stock. Monday covers all of them.

ATNM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ATNM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Actinium Pharmaceuticals, Inc. returned −18.6% against +6.9% for the S&P 500, dividends included.

ATNM vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26ATNMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ATNM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
0.0%
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
4.0×

Cheaper than 88% of US stocks

Price / sales
1.2×

Cheaper than 61% of US stocks

Price / book
5.4×

Cheaper than 17% of US stocks

EV / EBITDA
1.6×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
26.1%

Higher than 85% of US stocks

Net margin
30.3%

Higher than 88% of US stocks

Returns & dividend
Return on equity
55.2%

Higher than 94% of US stocks

Return on assets
12.9%

Higher than 95% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Actinium Pharmaceuticals, Inc. has a market value of $42.4M and an enterprise value of $14.9M.

  • Revenue in the twelve months to 30 June 2026: $35.1M.

  • Net income over the same four quarters: $11.3M, a 32.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$23.2M.

  • Shares outstanding: 31.4M.

  • Trailing P/E: 4.0×.

  • Actinium Pharmaceuticals, Inc. employs 25 people — $1.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ATNM and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ATNMActinium Pharmaceuticals, Inc.$42.4M87
VERUVeru, Inc.$33.1M51
GRDXGridAI Technologies Corp.$32.4M16
HYFTMindWalk Holdings Corp.$32.0M44
HYPDHyperion DeFi, Inc.$31.5M39
CUECue Biopharma, Inc.$34.7M20
FLNAFilana Therapeutics, Inc.$31.0M66

Take a look at ATNM’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Actinium Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ATNM

What is the ATNM stock price forecast for 2026-2027?

The median 12-month analyst price target for Actinium Pharmaceuticals, Inc. is $4, with estimates ranging from $3 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATNM stock a buy right now?

Of the 3 analysts covering Actinium Pharmaceuticals, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Actinium Pharmaceuticals, Inc. 87 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATNM?

As at 21 Nov 2026, Actinium Pharmaceuticals, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (100 of 100).

Will ATNM stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $4, and Ticker Nerd's factor model ranks Actinium Pharmaceuticals, Inc. 87 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATNM stock forecast for 2030?

No analyst covering Actinium Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATNM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $7 over the next 12 months.

How has ATNM stock performed over the past year?

Actinium Pharmaceuticals, Inc. returned -18.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Actinium Pharmaceuticals, Inc. do?

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for cancer. Its current pipeline centers on antibody radiation conjugates and actinium-225-based programs designed to deliver radiation directly to tumor cells while limiting exposure to healthy tissue.

Company

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for cancer. Its current pipeline centers on antibody radiation conjugates and actinium-225-based programs designed to deliver radiation directly to tumor cells while limiting exposure to healthy tissue. The company’s lead product candidate, ATNM-400, is being developed as a multi-indication therapy for solid tumors including prostate cancer, non-small cell lung cancer, and breast cancer. Actinium is also advancing Actimab-A for hematologic malignancies such as acute myeloid leukemia, along with Iomab-ACT for conditioning before gene and cell therapies. Through these programs, Actinium Pharmaceuticals, Inc. plays a specialized role in precision oncology, addressing both solid tumor and blood cancer settings with radiopharmaceutical approaches.

CEO Mr. Sandesh C. Seth M.B.A., M.S. · 25 employees · United States · https://www.actiniumpharma.com